USA flag logo/image

An Official Website of the United States Government

Development of a Test Cancer BioChip for the Cancer BioChip System

Award Information

Department of Health and Human Services
Award ID:
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
2661 Clearview Road, Suite 1 Allison Park, PA 15101
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2010
Title: Development of a Test Cancer BioChip for the Cancer BioChip System
Agency: HHS
Contract: 1R43CA141962-01A2
Award Amount: $269,640.00


DESCRIPTION (provided by applicant): Recent genomic breakthroughs have revolutionized our understanding of cancer. It is now possible to envision treatment paradigms that would be individualized, targeted and tailored according to the tumor genetic profile . However, high-throughput functional assays capable of identifying and validating potential cancer drugs, based on abnormal tumor gene expression profiles, in a setting that would directly translate to providing recommendations for patient treatment are n ot readily available. The human tumor stem cell assay (HTSCA), also known as anchorage-independent growth assay, has been considered as the gold standard for chemosensitivity testing of patient tumor cells. In its current format, the HTSCA suffers from m any pitfalls that make it unfit for high-throughput clinical testing. Falcon Genomics, Inc. is developing the Cancer BioChip System (CBCS), a rapid, high-throughput, automated, and quantitative anchorage-independent growth assay for the personalized identi fication and validation of inhibitors of cancer cell growth. We will use silencing RNA (siRNA) or short hairpin RNA (shRNA) to inhibit expression of abnormally expressed tumor genes and test their impact on anchorage-independent tumor growth in a high-thro ughput fashion. In this Phase I application, we will develop a Test Cancer BioChip for optimizing plating, transfection, silencing, and cytostatic efficiencies. Results from these studies will validate the CBCS as a tool for cancer target identification an d validation. Through future clinical trials, we anticipate development of the CBCS into a cancer diagnostic and personalized therapeutic tool. PUBLIC HEALTH RELEVANCE: This Phase-1 grant application is relevant to the mission of the National Instit ute of Health since it will provide for a Cancer BioChip System that will assist in the diagnosis and development of cancer therapies. It will initially offer a novel personalized approach to the evaluation and treatment of breast cancer patients. However, it is not limited to breast cancer since all types of cancers that are capable of growing in an anchorage-independent fashion can be tested on the Cancer BioChip System.

Principal Investigator:

Rula A. Abbudantaki

Business Contact:

Antaki R. Abbud
Small Business Information at Submission:

FALCON GENOMICS, INC. 160 North Craig Street, Suite 222 PITTSBURGH, PA 15213

EIN/Tax ID: 127010274
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No